KANEKA CORPORATION FY2027 Q1 Earnings Report

Quick View

Executive Summary

During the quarter, profit growth outpaced revenue growth, driven by revenue increases across all reported segments and operating leverage. Revenue was ¥2,230.2B (+12.3% YoY), Operating Income was ¥149.4B (+83.1%), Ordinary Income was ¥137.5B (+127.7%), and Net Income was ¥95.0B (+106.6%). The primary drivers of earnings growth were an improved gross margin and controlled growth in SG&A expenses (+10.0%, below the rate of revenue growth).

Factors Affecting Performance

【Revenue】Revenue was ¥2,230.2B, up +12.3% YoY. All four reported segments posted revenue growth, led by the Material Solutions Unit (¥945.5B, +14.7%) and the Health Care Solutions Unit (¥220.3B, +20.4%). In particular, Material Solutions accounted for more than half of the consolidated revenue increase and was the core driver of revenue growth.

【Profit and Loss】Operating Income was ¥149.4B, up +83.1% YoY, substantially exceeding the rate of revenue growth. The gross margin improved to 29.4% (27.3% in the prior-year period) due to a decline in the cost-of-sales ratio, while SG&A expenses increased by +10.0%, below the rate of revenue growth, resulting in margin expansion. Ordinary Income was ¥137.5B (+127.7%), below Operating Income as non-operating expenses, including ¥10.9B in interest expenses, exceeded non-operating income. Net Income was ¥95.0B (+106.6%), representing substantial earnings growth driven by improvements in the core business even without the ¥1.075B gain on the sale of investment securities recorded in the prior-year period. The Company recorded ¥3.3B in extraordinary losses (losses on disposal of fixed assets). The Company achieved both revenue and earnings growth, with the primary driver of earnings growth being improved profitability in the core business.

Segment Analysis

The Material Solutions Unit posted Revenue of ¥945.5B (+14.7%), Operating Income of ¥108.6B (+73.3%), and a profit margin of 11.5% (a substantial improvement YoY), making it the largest earnings-growth driver and accounting for 43.9% of total reported segment profit. The Quality of Life Solutions Unit posted Revenue of ¥538.8B (+11.1%), Operating Income of ¥70.1B (+34.5%), and a profit margin of 13.0%, showing steady improvement. The Nutrition Solutions Unit posted Revenue of ¥524.5B (+6.3%), Operating Income of ¥33.6B (+25.5%), and an improved profit margin of 6.4%. The Health Care Solutions Unit recorded the highest growth rate, with Revenue of ¥220.3B (+20.4%), but Operating Income increased only +11.3% to ¥34.9B, while its profit margin declined YoY to 15.8%, although it remained the highest among the four segments. The consolidated Operating Income margin was 6.7%, compared with an aggregate reported segment profit margin of approximately 11.1%; the difference is primarily attributable to ¥99.1B in company-wide expenses, mainly basic research and development expenses.

Key Financial Indicators

【Profitability】The Operating Income margin was 6.7%, an improvement of approximately 2.6pt YoY, while the gross margin was 29.4%, an improvement of 2.1pt. The Net Income margin was 4.3%, expanding by approximately 1.9pt YoY.【Cash Quality】Ordinary Income was 8.0% below Operating Income, reflecting a structure in which non-operating expenses, including ¥10.9B in interest expenses, exceeded non-operating income. Non-operating income was limited to 0.6% of Revenue, indicating limited reliance on temporary income.【Investment Efficiency】Annualized ROE was 7.2% and the Equity Ratio was 53.7%; capital efficiency is showing a gradual improvement trend despite the use of financial leverage.【Financial Soundness】The Equity Ratio of 53.7% declined slightly from 54.4% in the prior year but remained at a high level. The funding structure has become more short-term due to an increase in short-term borrowings (+10.0%).

Cash Flow Analysis

Although detailed cash flow statements are not included in this disclosure, the balance sheet movements provide insight into fund flows. Total assets increased to ¥9,830.1B (¥9,591.5B in the prior year), with increases in accounts receivable and inventories occurring alongside an increase in short-term borrowings. Inventories increased from the prior year, indicating accumulation of raw materials and finished products and suggesting efforts to secure inventory in response to revenue growth. Cash and deposits were ¥525.8B, showing a gradual increase from the prior year; however, compared with short-term borrowings of ¥1,534.7B, excess liquidity remains limited, and the speed of working-capital monetization will influence funding efficiency going forward.

Quality of Earnings

Non-operating income for the period was ¥13.9B, equivalent to only 0.6% of Revenue. Since its main components were ¥6.8B in dividend income and ¥3.4B in foreign exchange gains, reliance on temporary and non-recurring income is low. Ordinary Income of ¥137.5B was 8.0% below Operating Income of ¥149.4B, with non-operating expenses of ¥25.8B, including ¥10.9B in interest expenses, acting as a drag. Net Income of ¥95.0B reflects ¥39.2B in income taxes and other taxes, ¥5.5B in net income attributable to non-controlling interests, and ¥3.3B in extraordinary losses (losses on disposal of fixed assets) deducted from Ordinary Income. Given that the ¥1.075B gain on the sale of investment securities recorded in the prior-year period was absent in the current period, the current earnings growth can be viewed as high-quality, supported by expansion of Operating Income in the core business (+¥67.8B).

Earnings Forecast and Guidance

The full-year Company forecast is Revenue of ¥8,200B (+1.0% YoY), Operating Income of ¥360B (+9.4%), and Ordinary Income of ¥320B (+10.8%). Progress toward the full-year forecast in Q1 was 27.2% for Revenue, 41.5% for Operating Income, and 43.0% for Ordinary Income. Progress for Operating Income and Ordinary Income was well above the simple one-quarter benchmark of 25%, indicating a strong start. Meanwhile, the Operating Income margin assumed in the full-year plan is approximately 4.4%, below the 6.7% achieved in the current quarter, suggesting an assumption of margin normalization in subsequent quarters and a cautious incorporation of the business environment. No revisions have been made to the earnings forecast.

Shareholder Returns

The full-year dividend forecast is ¥210 per share, with no revision to the dividend forecast. The forecast Payout Ratio based on forecast full-year EPS of ¥523.04 is approximately 40.2%. As the dividend in the prior year was ¥80, the full-year forecast of ¥210 represents a substantial dividend increase. Net income attributable to owners of the parent in the current quarter reached 28.4% of the full-year forecast, indicating generally steady earnings progress supporting the dividend forecast.

Risk Factors

1. Funding Structure Risk: Short-term borrowings of ¥1,534.7B account for the majority of interest-bearing debt, resulting in a high short-term debt ratio. Cash and deposits of ¥525.8B are below short-term borrowings, and changes in refinancing conditions or funding costs could affect liquidity management.

2. Profitability of Health Care Solutions: Revenue grew strongly by +20.4% YoY, but Operating Income increased only +11.3%, and the profit margin declined from the prior year. Monetizing growth, as well as product mix and cost management, remains a challenge.

3. Raw Material and Commodity Market Risk: As the Material Solutions Unit accounts for the core of reported segment profit, fluctuations in raw material and energy prices and in supply-demand conditions have a relatively significant impact on consolidated earnings.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Company’s profit margins are below the industry median but are close to the lower bound of the IQR. The improvement trend from the prior year is worthy of recognition.

Growth and Capital Efficiency

The Revenue growth rate substantially exceeded the industry median and showed strong growth close to the upper bound of the IQR.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Operating Income increased by 83.1% against revenue growth of 12.3%, clearly demonstrating a recovery in profitability through gross-margin improvement and controlled SG&A growth. The Material Solutions Unit was the core driver of earnings growth, while the other segments also generally contributed to margin improvement.

2. Progress toward the full-year Operating Income forecast was high at 41.5%, indicating a strong start. However, the profit margin assumed in the full-year plan is below the current-quarter result, making the maintenance of profitability in subsequent quarters key to achieving the full-year target.

3. Dependence on short-term borrowings is high, and cash and deposits are below short-term borrowings. Even during a period of revenue and earnings growth, monitoring working capital and the funding structure remains important from the perspective of financial soundness.

Theoretical Share Price (Reference Value)

Sensitivity: ¥7,853–¥8,309 at ±1% for the cost of equity, and ¥8,053–¥8,092 at ±0.1 for ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value will be below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, nor does it forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---